Antibodies to Bufalin Prevent Na/K ATPase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with decreased Na/K ATPase activity, such as hemorrhagic shock, septic shock, and cardiovascular diseases, are inadequate due to the inability to effectively manage bufadienolide-induced inhibition of Na/K ATPase, leading to cellular depolarization and fluid imbalance.
Innovation Solution
Administration of a therapeutically effective amount of molecules like polyclonal or monoclonal antibodies or antigen binding fragments that inhibit or stimulate the immune system to target bufadienolides, specifically bufalin, to restore or maintain Na/K ATPase activity, thereby counteracting the inhibitory effects on the enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional resuscitation methods (fluid infusion) are used to treat hemorrhagic shock, then blood volume is restored and oxygen delivery is improved, but the underlying cause (bufadienolide-induced Na/K ATPase inhibition) is not addressed, leading to continued cellular depolarization and fluid imbalance
Solution Approach 1:
The patent introduces antibodies as intermediary substances that specifically bind to bufadienolides, preventing them from inhibiting Na/K ATPase. This intermediary approach neutralizes the harmful substance without directly affecting the enzyme, allowing physiological processes to恢复正常 while addressing the root cause of shock
Solution Approach 2:
The patent converts the harmful effect of bufadienolides into a beneficial therapeutic opportunity by using the immune system to produce antibodies against them. The same substance that causes shock (bufadienolide) becomes the target of a therapeutic intervention (antibody therapy), transforming the harmful pathway into a治愈 mechanism
2Stability of the object's composition
If large volumes of fluid are infused to restore blood volume in hemorrhagic shock, then cardiovascular stability is improved, but cellular fluid imbalance and depolarization persist due to ongoing Na/K ATPase inhibition
Solution Approach 1:
The patent transforms the harmful bufadienolide substance into a therapeutic target by inducing antibody production. The same substance causing cellular depolarization becomes the antigen that triggers a protective immune response, converting the harmful pathway into a治愈 mechanism that restores cellular function
Solution Approach 2:
Antibodies serve as intermediary molecules that specifically bind to bufadienolides in the circulation, preventing them from reaching and inhibiting Na/K ATPase at the cellular level. This intermediary approach protects cells from the harmful substance while allowing systemic fluid resuscitation to stabilize cardiovascular function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively prolongs survival in hemorrhagic shock and alleviates symptoms in conditions characterized by decreased Na/K ATPase activity by preventing bufadienolide-induced inhibition, thereby maintaining cellular homeostasis and restoring vital functions.
Implementation Method 1
Administration of a therapeutically effective amount of molecules like polyclonal or monoclonal antibodies or antigen binding fragments that inhibit or stimulate the immune system to target bufadienolides, specifically bufalin
Data Source
AI summary
The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and/or bufalin sulfate, or vaccination against bufalin and/or bufalin sulfate, which prevents or attenuates inhibition of Na/K ATPase activity thereby attenuating the adverse physiological effects of bufalin and/or bufalin sulfate inhibition. The invention also relates to methods of treating hemorrhagic, septic shock, cardiogenic shock, shock resulting from physical trauma, diabetes, mental depression, bipolar disorder and schizophrenia comprising administering a therapeutically effective amount of an bufalin monoclonal or polyclonal antibody.